Cholangiocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Biliary Tract Cancer (321)

Gallbladder Cancer (41)

Biliary Tract Cancer (321)

Gallbladder Cancer (41)

›

HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 3 days (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 3d	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 3 days BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 3 days - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week (New C3) futibatinib Sensitive : A1 N Engl J Med - 1wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week futibatinib Sensitive : A1 N Engl J Med - 1 week - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week (New C3) futibatinib Sensitive : A1 N Engl J Med - 1wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week futibatinib Sensitive : A1 N Engl J Med - 1 week - (New C3)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 1 week (New C4) palbociclib Sensitive : C4 Onco Targets Ther - 1wk	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 1 week palbociclib Sensitive : C4 Onco Targets Ther - 1 week - (New C4)
CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	capmatinib Sensitive: C4 – Case Studies The Oncologist - 1 week (New C4) capmatinib Sensitive : C4 The Oncologist - 1wk	capmatinib Sensitive: C4 – Case Studies The Oncologist - 1 week capmatinib Sensitive : C4 The Oncologist - 1 week - (New C4)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C2 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Cholangiocarcinoma	MDM2 amplification	Cholangiocarcinoma	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C3 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C3 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B
HER-2 expression	Cholangiocarcinoma	HER-2 expression	Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	TT-00420 Sensitive: B - Late Trials TT-00420 Sensitive : B	TT-00420 Sensitive: B - Late Trials TT-00420 Sensitive : B
RET fusion	Cholangiocarcinoma	RET fusion	Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
BRCA2 mutation	Cholangiocarcinoma	BRCA2 mutation	Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Cholangiocarcinoma	BRCA1 mutation	Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
NTRK3 fusion	Cholangiocarcinoma	NTRK3 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Cholangiocarcinoma	NTRK2 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Cholangiocarcinoma	NTRK1 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
BRAF V600	Cholangiocarcinoma	BRAF V600	Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
MSI-H/dMMR	Cholangiocarcinoma	MSI-H/dMMR	Cholangiocarcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
BRAF V600E	Cholangiocarcinoma	BRAF V600E	Cholangiocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
NTRK2 fusion	Cholangiocarcinoma	NTRK2 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Cholangiocarcinoma	NTRK3 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK1 fusion	Cholangiocarcinoma	NTRK1 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
HER-2 overexpression	Cholangiocarcinoma	HER-2 overexpression	Cholangiocarcinoma	lapatinib Sensitive: C1 - Off-label lapatinib Sensitive : C1	lapatinib Sensitive: C1 - Off-label lapatinib Sensitive : C1
BRAF V600E	Cholangiocarcinoma	BRAF V600E	Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
FGFR2 translocation	Cholangiocarcinoma	FGFR2 translocation	Cholangiocarcinoma	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 amplification	Cholangiocarcinoma	FGFR2 amplification	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2

Cholangiocarcinoma

Associations(181)

Associations
(181)